- Home
- MRSN vs NAUT Comparison
MRSN vs NAUT Comparison
Compare MRSN & NAUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- NAUT
- Stock Information
- Founded
- MRSN 2001
- NAUT 2016
- Country
- MRSN United States
- NAUT United States
- Employees
- MRSN N/A
- NAUT N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- NAUT Biotechnology: Laboratory Analytical Instruments
- Sector
- MRSN Health Care
- NAUT Industrials
- Exchange
- MRSN Nasdaq
- NAUT Nasdaq
- Market Cap
- MRSN 252.0M
- NAUT 284.7M
- IPO Year
- MRSN 2017
- NAUT N/A
- Fundamental
- Price
- MRSN $1.86
- NAUT $2.03
- Analyst Decision
- MRSN Buy
- NAUT Hold
- Analyst Count
- MRSN 6
- NAUT 3
- Target Price
- MRSN $6.00
- NAUT $3.58
- AVG Volume (30 Days)
- MRSN 1.1M
- NAUT 130.0K
- Earning Date
- MRSN 11-13-2024
- NAUT 10-29-2024
- Dividend Yield
- MRSN N/A
- NAUT N/A
- EPS Growth
- MRSN N/A
- NAUT N/A
- EPS
- MRSN N/A
- NAUT N/A
- Revenue
- MRSN $34,837,000.00
- NAUT N/A
- Revenue This Year
- MRSN N/A
- NAUT N/A
- Revenue Next Year
- MRSN N/A
- NAUT N/A
- P/E Ratio
- MRSN N/A
- NAUT N/A
- Revenue Growth
- MRSN N/A
- NAUT N/A
- 52 Week Low
- MRSN $1.22
- NAUT $1.88
- 52 Week High
- MRSN $6.28
- NAUT $3.46
- Technical
- Relative Strength Index (RSI)
- MRSN 42.16
- NAUT 37.08
- Support Level
- MRSN $1.93
- NAUT $1.90
- Resistance Level
- MRSN $2.81
- NAUT $2.21
- Average True Range (ATR)
- MRSN 0.24
- NAUT 0.14
- MACD
- MRSN -0.05
- NAUT -0.01
- Stochastic Oscillator
- MRSN 7.79
- NAUT 16.81
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.